Getinge AB Class B GETI_B

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Neonatal Intensive Care Respiratory Devices Market size & share revenue was valued at approximately USD 2.1 Billion in 2025 and is expected to reach USD 2.3 Billion in 2026 and is expected to reach around USD 5.7 Billion by 2035, at a CAGR of 10.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Inspirat

Getinge today announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. Designed for clinicians, by clinicians, the system represents the latest evolution of Getinge's EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures.

In May 2026, Avantor, Inc. appointed Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory, giving him global responsibility for quality assurance, quality systems, and regulatory affairs across all of the company’s businesses. Porreca’s extensive background in steering complex global approvals and regulatory transformations at Getinge, Becton Dickinson, C.R. Bard, and Smith+Nephew adds experienced leadership in areas that are increasingly critical for life sciences...

Getinge today announces that a jury in the United States District Court for the District of Massachusetts has delivered a verdict in favor of Abiomed Inc ("Abiomed") in a patent dispute between Getinge's subsidiary Maquet Cardiovascular LLC ("Maquet") and Abiomed. The jury found that Abiomed has not infringed any Maquet patents relating to intravascular heart pump technology.

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Gerard (Jerry) Porreca has joined the company as Executive Vice President, Quality and Regulatory.

The global neonatal ventilators market is projected to grow at a CAGR of 4.63% between 2025 and 2031. Key segments include consumables & accessories, non-invasive ventilators, standalone ventilators, and hospital end-users. North America leads the market, with the U.S. holding 87% by 2025. Industry highlights include GE HealthCare's acquisition of Intelerad and Philips’ strategic alliances to enhance clinical workflows. Innovations like Hamilton Medical's HAMILTON-C6 Neo ventilator support marke

Getinge (OM:GETI B) plans significant board changes at its 2026 AGM. Shareholders are set to vote on the election of Camilla Sylvest to the board. New employee representatives are also expected to join the board, reshaping its composition. Getinge, a global provider of medical technology and life science solutions, is closely watched by investors who follow corporate governance and board expertise. Changes to the board at the 2026 AGM put the focus on how the company aligns oversight with...

Despite currency and tariff challenges, Getinge AB (GNGBY) reports solid cash flow and strategic product launches to bolster future growth.

"We succeeded in surpassing last year's record-breaking first quarter with organic growth in both net sales and order intake," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased organically by 0.8% while the order intake rose by 3.9% organically.

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Anesthesia and Respiratory Devices Market size & share revenue was valued at approximately USD 57.2 Billion in 2025 and is expected to reach USD 60.5 Billion in 2026 and is expected to reach around USD 100.5 Billion by 2035, at a CAGR of 5.8% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Medtronic, O2

Today, Getinge publishes its Annual Report for 2025, including the Sustainability statement. The year was marked by geopolitical friction and significant cost impacts from tariffs and currency movements, while the company delivered strong underlying profitability, continued regulatory progress, and an ambitious innovation agenda.